Targeting GOT1 or disruption of this pathway has been reported to cause a decrease in the NAD+/NADH ratio, increase in the NADP+/NADPH ratio and reduced ATP production, collectively contributing to suppression of cancer cell proliferation and enhancement of sensitivity to anti-tumor therapies [12–15]. The gene discussed is GOT1; the disease is cancer.